(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s action in the House Judiciary Committee on legislation aimed at increasing competition in the prescription drug marketplace. “We applaud the House Judiciary
(Washington, D.C.) — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics that increase prescription drug costs for patients. The report, conducted by the research firm Visante,
Lawmakers Reintroduce Bill to Close Loopholes Allowing Big Drug Companies to Block Competition from More Affordable Options The Pharmaceutical Care Management Association, PCMA, applauds Senators Maggie Hassan (D-NH) and Mike Braun (R-IN) for recently reintroducing legislation, the Prescription Drug Competition Act,
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re highlighting new reputable third-party research and analyses by economists which underscore that legislation focused on
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case you missed it, Senator Rand Paul (R-KY) discusses recent legislation advanced by the Senate’s HELP
Alex Brill and Angela Banks Dive into the Critical Need for Competition, Big Drug Companies’ Abuse of the Patent System, and Biosimilar Adoption In case you missed it, Angela Banks, Vice President of Policy for the Pharmaceutical Care Management Association
A recent white paper (“The Association Between Drug Rebates and List Prices”) narrowly suggests an association between list prices for brand drugs and the rebate practices of pharmacy benefit managers (PBMs) and insurers, despite an underlying methodology that is notably broader
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Office of Inspector General’s proposed rule on prescription drug rebates in Medicare: “While we are reviewing the proposed
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that drug companies are the root cause of high prescription drug prices is one common denominator
©2024 PCMA. All Rights Reserved.
